RedHill Biopharma Ltd. ADR | Key People and Executives
Dror Ben-Asher
Chairman & Chief Executive Officer
Nicolás Alejandro Weinstein Díaz
Director
Richard D. Scruggs
Director
Eric Emile Swenden
Director
Nurit Benjamini
Independent Director
Ofer Tsimchi
Independent Director
Dan S. Suesskind
Independent Director
Shmuel Cabilly
Independent Director
Dror Ben-Asher
Chairman & Chief Executive Officer
Gilead Raday
Chief Operating Officer
Micha Ben-Chorin
Chief Financial Officer
Terry F. Plasse
Medical Director
Ira N. Kalfus
Medical Director
Reza Fathi
Senior Vice President-Research & Development
Danielle Abramson
Vice President-Intellectual Property & Research
David Wasserman
VP-Business Alliance & Compliance Officer
Aida Bibliowicz
Vice President-Clinical Affairs, Europe
Guy Goldberg
Chief Business Officer
Patrick Laughlin McLean
Product Manager
Adi Frish
Senior VP-Business Development & Licensing
Nicolás Alejandro Weinstein Díaz
Director
Richard D. Scruggs
Director
Eric Emile Swenden
Director
Valerie Graceffa
Vice President-United States Sales & Marketing
Uri Hananel Aharon
Chief Accounting Officer
Shani Maurice
VP-Business Development & Communications
Patricia Anderson
Vice President-Regulatory Affairs
Nurit Benjamini
Independent Director
Ofer Tsimchi
Independent Director
Dan S. Suesskind
Independent Director
Shmuel Cabilly
Independent Director
| Address |
21 Ha'arba'a Street
Tel Aviv TA 64739
Israel
|
|
Employees
|
- |
| Website |
http://www.redhillbio.com |
| Updated |
07/08/2019 |
| RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases. RedHill's pipeline includes several drug candidates in advanced clinical development stages, including three Phase III-stage programs. Its late clinical-stage pipeline includes TALICIA® (RHB-105) for Helicobacter pylori infection; RHB-104 for Crohn's disease; RHB-204 for nontuberculous mycobacteria (NTM) infections; BEKINDA® (RHB-102) for acute gastroenteritis and gastritis and IBS-D; YELIVA® (ABC294640) for cholangiocarcinoma and targeting multiple other oncology, inflammatory and gastrointestinal indications; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd. and RHB-107, targeting cancer and inflammatory gastrointestinal diseases. |
